发明名称 |
Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir |
摘要 |
Gene therapy with genes for prodrug converting enzymes adds to local control of glioblastoma achieved by surgery. There appears to be a pronounced local reaction which is in part inflammatory and has a measurable immunological component. Considering the widely proven fact that during the weekslong gap-phase between surgery and completion of radiation or chemoradiation tumour growth from the infiltrative zone may continue unhampered, a treatment such as SIT will cover that time period. |
申请公布号 |
US2016058888(A1) |
申请公布日期 |
2016.03.03 |
申请号 |
US201414787887 |
申请日期 |
2014.05.08 |
申请人 |
FINVECTOR VISION THERAPIES LIMITED ;PHARMACEUTICAL PATENT ATTOENEYS, LLC. |
发明人 |
Yla-Herttuala Seppo |
分类号 |
A61K48/00;A61K31/522;A61K38/45;A61K31/495 |
主分类号 |
A61K48/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. In a method of treating glioblastoma in a human by surgical resection and temozolomide, an improvement comprising:
b. administering locally about the surgical resection site after surgical resection, about 1×1012 particles of replication-deficient adenovirus serotype 5 with E1 and partial E3 deletions, and containing the cDNA for HSV-tk which is able to phosphorylate ganciclovir, then c. administering gancyclovir 5 mg/kg i.v., twice daily. |
地址 |
Chinnor, Oxfordshire GB |